News
There’s an old maxim, “the secret to happiness is low expectations.” This saying could not apply more directly than to what we are seeing...
Hi, what are you looking for?
iFintechWorld
iFintechWorld
News
This article was written by Follow Buyside analyst covering global stocks on Seeking Alpha since 2018. I’ve been investing personally and professionally across major...
News
This article was written by Follow Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish...
News
This article was written by Follow Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish...
News
By James Smith, Developed Markets Economist Some good news on inflation for once If you’re looking for some good news on the UK inflation...
News
A few months ago, I wrote a cautious article on the Hoya Capital High Dividend Yield ETF (RIET). While RIET’s 10% distribution yield was...
News
Investment thesis Our current investment thesis is: JHG has struggled with growth, as investors are increasingly unconvinced by the value offered by active management....
News
Introduction ImmunoGen (NASDAQ:IMGN) is a commercial-stage biotech firm focused on developing innovative antibody-drug conjugates (ADCs) to enhance cancer treatment. These targeted therapies boast improved...
News
Levi Strauss & Co. (NYSE:LEVI) Q2 2023 Earnings Call Transcript July 6, 2023 5:00 PM ET Company Participants Aida Orphan – Vice President, Investor...
News
Buckle Up They giveth and then they taketh. As we reported last month, insiders jumped into June with both feet. In what turned out...
News
An extremely hot June gave way to an even steamier July, with this week setting the record for the steepest global average temperatures. That...
News
Intro Churchill Downs Incorporated (NASDAQ:CHDN) is a prominent entertainment company in the United States that operates in the racing, online wagering, and gaming sectors....
News
The Food and Drug Administration (FDA) has granted final approval to the anti-Alzheimer’s drug lecanamab, marked as Leqembi by drugmakers Eisai and Biogen BIIB...
